Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Li, Jonathan Z ^a   Chapman, Brad ^b   Charlebois, Patrick ^c   Hofmann, Oliver ^b   Weiner, Brian ^c   Porter, Alyssa J ^b   Samuel, Reshmi ^a,d   Vardhanabhuti, Saran ^b   Zheng, Lu ^b   Eron, Joseph ^e   Taiwo, Babafemi ^f   Zody, Michael C ^c   Henn, Matthew R ^c   Kuritzkes, Daniel R ^a   Hide, Winston ^b   Matining, Roy M ^b   Wilson, Cara C ^g   Berzins, Baiba I ^f   Acosta, Edward P ^h   Bastow, Barbara ⁱ   Kim, Peter S ^j   Read, Sarah W ^j   Janik, Jennifer ^k   Meres, Debra S ^j   Lederman, Michael M ^l   Mong Kryspin, Lori ^m   Shaw, Karl E ⁿ   Zimmerman, Louis G ^o   Leavitt, Randi ^p   De La Rosa, Guy ^q   Jennings, Amy ^r   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k Frontier Science and Technology Research Foundation   (United States)

^l CASE WESTERN RESERVE UNIVERSITY   (United States)

^m OHIO STATE UNIVERSITY   (United States)

ⁿ HENRY FORD HOSPITAL   (United States)

^o University of Colorado CRS   (United States)

^p MERCK RESEARCH LABORATORIES   (United States)

^q Merck ^*  (United States)

^r ACTG Operations Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; INTEGRASE; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

454 DEEP SEQUENCING; ACCURACY; ANALYZER; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLONE; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; ILLUMINA SEQUENCING; INTERMETHOD COMPARISON; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIROLOGY; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HIGH THROUGHPUT SEQUENCING; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; PHYSIOLOGY; PROCEDURES; TREATMENT FAILURE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PYRROLIDINONES; TREATMENT FAILURE;

EID: 84897392253     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090485     Document Type: Article

References (23)

1. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, et al. (1993) Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365: 671-673.
2. Church JD, Jones D, Flys T, Hoover D, Marlowe N, et al. (2006) Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 8: 430-432; quiz 527.
3. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305: 1327-1335.
4. Boltz VF, Zheng Y, Lockman S, Hong F, Halvas EK, et al. (2011) Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A 108: 9202-9207.
5. Karow J (January 19, 2010) Survey: Illumina, SOLiD, and 454 Gain Ground in Research Labs; Most Users Mull Additional Purchases. In Sequence.
6. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. (Feb 12, 2013) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1-239.
7. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW (2011) HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 203: 1204-1214.
8. Codoner FM, Pou C, Thielen A, Garcia F, Delgado R, et al. (2010) Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res 88: 281-286.
9. Charpentier C, Laureillard D, Piketty C, Tisserand P, Batisse D, et al. (2010) High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 24: 867-873.
10. Liu J, Miller MD, Danovich RM, Vandergrift N, Cai F, et al. (2011) Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother 55: 1114-1119.
11. Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, et al. (2012) Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis 205: 557-567.
12. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, et al. (2011) Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 25: 2113-2122.
13. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297-1303.
14. Lakhani KR, Boudreau KJ, Loh PR, Backstrom L, Baldwin C, et al. (2013) Prize-based contests can provide solutions to computational biology problems. Nat Biotechnol 31: 108-111.
15. Macalalad AR, Zody MC, Charlebois P, Lennon NJ, Newman RM, et al. (2012) Highly sensitive and specific detection of rare variants in mixed viral populations from massively parallel sequence data. PLoS Comput Biol 8: e1002417.
16. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, et al. (2012) Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog 8: e1002529.
17. Zagordi O, Daumer M, Beisel C, Beerenwinkel N (2012) Read length versus depth of coverage for viral quasispecies reconstruction. PLoS One 7: e47046.
18. Archer J, Weber J, Henry K, Winner D, Gibson R, et al. (2012) Use of Four Next-Generation Sequencing Platforms to Determine HIV-1 Coreceptor Tropism. PLoS One 7: e49602.
19. Luo C, Tsementzi D, Kyrpides N, Read T, Konstantinidis KT (2012) Direct comparisons of Illumina vs. Roche 454 sequencing technologies on the same microbial community DNA sample. PLoS One 7: e30087.
20. Archer J, Baillie G, Watson SJ, Kellam P, Rambaut A, et al. (2012) Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II. BMC Bioinformatics 13: 47.
21. Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, et al. (2010) Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother 54: 3938-3948.
22. Mukherjee R, Jensen ST, Male F, Bittinger K, Hodinka RL, et al. (2011) Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS 25: 1951-1959.
23. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R (2011) Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci U S A 108: 20166-20171.